Skip to main content
For Healthcare
Professionals
Therapeutic areas
Products
Resources
Events
Contact
English (United Kingdom)
Therapeutic areas
Haematology
Immunology
Specialty Care portfolio
Products
Aspaveli®▼ (pegcetacoplan)
Doptelet® (avatrombopag)
Orfadin® (nitisinone)
Tegsedi® (inotersen)
Zynlonta®▼ (loncastuximab tesirine)
Resources
Events
Contact
Events
Home
Events
PP-20151
Sep, 2023
Therapeutic areas
Haematology
Haemophilia
Immune thrombocytopenia (ITP)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Immunology
Interleukin-1 and autoinflammatory diseases
Specialty Care portfolio
Products
Aspaveli®▼ (pegcetacoplan)
Doptelet® (avatrombopag)
About ITP
Challenge expectations
Efficacy
Speed of onset and sustainability of response
Consistency of response
Effectiveness following switch from other TPO-RA
Dosing
Safety profile
Guidelines
Resource centre
Orfadin® (nitisinone)
Tegsedi® (inotersen)
Zynlonta®▼ (loncastuximab tesirine)
Home
Efficacy
2-year follow up data
Dosing and administration
Overall Safety Profile
Non-haematological TEAEs
Haematological & laboratory TEAEs
Special warnings and precautions for use
Resources
Expert opinion videos
Real World Experience case studies
BSH 2024 highlights
Resources
Events
Contact
Login
Other sites
expand_less
